|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 207/26 | (2006.01) |
| C07D 207/273 | (2006.01) | ||
| C07D 209/52 | (2006.01) | ||
| C07D 215/48 | (2006.01) | ||
| C07D 217/02 | (2006.01) | ||
| C07D 217/22 | (2006.01) | ||
| C07D 217/24 | (2006.01) | ||
| C07D 239/86 | (2006.01) | ||
| C07D 239/88 | (2006.01) | ||
| C07D 263/24 | (2006.01) | ||
| C07D 401/12 | (2006.01) | ||
| C07D 401/14 | (2006.01) | ||
| C07D 403/12 | (2006.01) | ||
| C07D 405/12 | (2006.01) | ||
| C07D 405/14 | (2006.01) | ||
| C07D 413/12 | (2006.01) |
| (11) | Number of the document | 3126330 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15717250.3 |
| Date of filing the European patent application | 2015-03-26 | |
| (97) | Date of publication of the European application | 2017-02-08 |
| (45) | Date of publication and mention of the grant of the patent | 2019-02-27 |
| (46) | Date of publication of the claims translation | 2019-04-25 |
| (86) | Number | PCT/IB2015/052251 |
| Date | 2015-03-26 |
| (87) | Number | WO 2015/150995 |
| Date | 2015-10-08 |
| (30) | Number | Date | Country code |
| 201461975473 P | 2014-04-04 | US |
| (72) |
ANDERSON, David Randolph, US
BUNNAGE, Mark Edward, US
CURRAN, Kevin Joseph, US
DEHNHARDT, Christoph Martin, CA
GAVRIN, Lori Krim, US
GOLDBERG, Joel Adam, US
HAN, Seungil, US
HEPWORTH, David, US
HUANG, Horng-Chih, US
LEE, Arthur, US
LEE, Katherine Lin, US
LOVERING, Frank Eldridge, US
LOWE, Michael Dennis, US
MATHIAS, John Paul, US
PAPAIOANNOU, Nikolaos, US
PATNY, Akshay, US
PIERCE, Betsy Susan, US
SAIAH, Eddine, US
STROHBACH, Joseph Walter, US
TRZUPEK, John David, US
VARGAS, Richard, US
WANG, Xiaolun, US
WRIGHT, Stephen Wayne, US
ZAPF, Christoph Wolfgang, US
|
| (73) |
Pfizer Inc.,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip IRAK4 inhibitorių |
| BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS |
| Payment date | Validity (years) | Amount | |
| 2024-02-09 | 10 | 231.00 EUR |
| 2025-03-26 |